ATHENS, Ga., March 3, 2022 /PRNewswire/ -- Athena Bioscience, LLC announced plans for the commercial launch of Nexiclon XR, the only once-daily clonidine extended-release tablets indicated for treatment of hypertension.1 Athena acquired exclusive rights to commercialize the product from Tris Pharma, Inc. in February 2021. The launch is set for April 2022 in all 50 U.S. states.
ATHENS, Ga., Feb. 22, 2022 /PRNewswire/ -- Sabal therapeutics, LLC announced today that they have entered into an exclusive sales and marketing agreement with Athena Bioscience, LLC to promote Athena's cardiovascular product portfolio. The commercial launch for two products, Nexiclon™ XR and Fibricor®, will occur in April 2022.
Athena Bioscience, LLC, a specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has approved QDOLOâ„¢ (tramadol hydrochloride) Oral Solution 5mg/1mL C-IV, an opioid agonist indicated in adults for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.